A randomized controlled trial on corticosteroid therapy for HTLV-1-associated myelopathy/tropical spastic paraparesis in Japan (HAMLET-P trial)

Authors:
Yamauchi J1,2, Sato T1,2, Yagishita N1, Araya N1, Nakagawa M3, Matsuura E4, Tsuboi Y5, Tamaki K5, Sakima H6, Ishihara S6, Araujo A7, Jacobson S8, Grassi MFR9,10, Galvão-Castro B9,10, Bland M11, Taylor GP12, Martin F13, Yamano Y1,2

1. Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
2. Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
3. Department of Neurology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
4. Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
5. Department of Neurology, Fukuoka University, Fukuoka, Japan.
6. Department of Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
7. Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
8. Viral immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, US.
9. Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.
10. Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil.
11. Department of Health Sciences, Seebohm Rowntree Building, University of York, York, UK.
12. Section of Virology, Department of Infectious Disease, Imperial College London, London, UK.
13. School of Public Health, Faculty of Medicine, University of Queensland, Herston QLD 4006, Australia.

Background/Purpose:
Corticosteroids are most commonly used to treat HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, their clinical efficacy has not been tested in randomized clinical trials.

Approach:
This multicenter, randomized controlled trial included 8 and 30 HAM/TSP patients with rapidly and slowly progressing walking disability, respectively. Rapid progressors were assigned (1:1) to receive or not receive a 3-day course of intravenous methylprednisolone in addition to oral prednisolone therapy. Meanwhile, slow progressors were assigned (1:1) to receive oral prednisolone or placebo. The primary outcomes were a composite of ≥1-grade improvement in the Osame Motor Disability Score (OMDS) or ≥30% improvement in the 10-meter walking time (10mWT) at week-2 for rapid progressors and changes from baseline in 10mWT at week-24 for slow progressors.

Outcomes/Impact:
In the rapid progressor trial, all four patients receiving intravenous methylprednisolone but none of those receiving oral prednisolone alone experienced improvement in OMDS. One patient in each treatment arm experienced improvement in 10mWT. Therefore, four and one patients with and without intravenous methylprednisolone achieved the primary outcome, respectively (p = 0.14). In slow progressor trial, the median changes from baseline in 10mWT were -13.8% (95% CI: -20.1 to -7.1; p < 0.001) and -6.0% (95% CI: -12.8 to -1.3; p = 0.10) with prednisolone and placebo, respectively (p for between-group difference = 0.12).

**Innovation and Significance:**
Whereas statistical significance was not reached for the primary efficacy endpoints due to the small sample size, the data overall indicate the benefit of corticosteroid therapy in patients with HAM/TSP.

**Disclosure of Interest Statement:**
*None.*